Every 8-K that Pharmacyte Biotech Inc (PMCB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PMCB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMCB filings page.
PharmaCyte Biotech, Inc. reported results of its annual stockholder meeting held by webcast. Stockholders approved all five proposals, including an amendment to the 2022 Equity Incentive Plan that increases the shares of common stock available for awards by 2,000,000.
Five directors were elected to serve until the next annual meeting, each receiving over 3.3 million votes in favor, with broker non-votes recorded. Stockholders also ratified CBIZ CPAs P.C. as independent auditor for the fiscal year ending April 30, 2026.
Investors approved, on a non-binding advisory basis, the compensation of the named executive officers. They further authorized the board, but did not require it, to implement a reverse stock split of the outstanding common stock at any ratio between 1-for-1.1 and 1-for-100.
PharmaCyte Biotech, Inc. filed an amended Form 8-K to supplement its earlier disclosure about a strategic investment in Q/C Technologies, Inc. The company previously purchased Q/C Series H convertible preferred stock and warrants for an aggregate price of $3,000,000, with the preferred shares convertible into 600,000 Q/C common shares and the warrants exercisable for up to 600,000 additional Q/C common shares. The amendment adds Q/C’s audited financial statements for the years ended December 31, 2024 and 2023, unaudited financials as of June 30, 2025, and unaudited pro forma condensed combined financial information showing how the Transaction would have affected PharmaCyte’s results. The pro forma data are presented for informational and illustrative purposes only and are not projections of future performance.
PharmaCyte Biotech (PMCB) reported shareholder approvals from its October 30, 2025 special meeting. Stockholders authorized, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of common stock underlying convertible preferred stock and warrants issued under the August 17, 2025 Securities Purchase Agreement and related placement engagement, in an amount equal to or in excess of 20% of common shares outstanding before those issuances, including any anti-dilution adjustments.
Shareholders also approved an amendment to the 2022 Equity Incentive Plan to increase the number of shares available for awards by 2,250,000 shares. Voting results: Proposal 1 passed with 1,649,395 for, 249,100 against, 47,316 abstaining; Proposal 2 passed with 2,348,827 for, 399,696 against, 118,421 abstaining; and adjournment authority (Proposal 3) passed with 2,496,898 for, 311,836 against, 58,210 abstaining. A quorum was present with 2,866,944 shares represented, approximately 37.1% of shares entitled to vote.
PharmaCyte Biotech, Inc. entered into a Securities Purchase Agreement for a private placement of 7,000 shares of new Series C convertible preferred stock with a stated value of $1,000 per share, for expected gross proceeds of $7 million. The preferred stock is initially convertible at $1.00 into up to 7,000,000 shares of common stock and is accompanied by warrants to purchase up to 7,000,000 additional common shares at an exercise price of $1.00, both with anti-dilution adjustments.
The preferred carries a 7% annual cash dividend, increasing to 15% upon certain Triggering Events, and votes with common stock based on stated value divided by the then-current conversion price, subject to Nasdaq “Minimum Price” constraints. Issuance above 19.99% of outstanding common stock requires Nasdaq stockholder approval, which the company plans to seek at a meeting no later than October 31, 2025. PharmaCyte will file a resale registration statement for 150% of the conversion shares and 150% of the warrant shares and may owe liquidated damages if it misses registration milestones.